Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
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
MtwqUBgkHZpw9HBB
